Management ChangeJun 2, 2026, 09:11 AM
Oncolytics Biotech Appoints COO John McAdory, Adds Stephen Glover to Board
AI Summary
Oncolytics Biotech Inc. announced the appointment of John McAdory as Chief Operating Officer, effective June 1, 2026. Mr. McAdory, previously the company's Executive Vice President, Strategy and Operations, will oversee clinical operations, development, and strategic partnerships. Additionally, Stephen Glover was appointed as the ninth director to the Board, bringing over 35 years of biopharmaceutical leadership experience, including guiding Ambrx Biopharma through its $2 billion acquisition. Both appointments are expected to strengthen the company's operational execution and strategic growth.
Key Highlights
- John McAdory appointed Chief Operating Officer of Oncolytics Biotech, effective June 1, 2026.
- Mr. McAdory previously served as EVP, Strategy and Operations, and VP, Clinical Operations at CG Oncology.
- Stephen Glover appointed as the ninth director to the Board of Directors, effective June 1, 2026.
- Mr. Glover was granted an option to purchase 96,000 shares, vesting in equal installments over three years.
- Mr. Glover brings over 35 years of leadership experience, including Chairman of Ambrx Biopharma during its $2 billion acquisition by Johnson & Johnson.
- He also serves as Co-Founder, Chairman, CEO, and President of ZyVersa Therapeutics.
- Both appointees entered into indemnification agreements with Oncolytics Biotech.
Price Impact
More from ONCY